Grindeks

AS Grindeks

company logo
Type
Traded as	Nasdaq Baltic: GRD1R
Industry	Pharmaceuticals
Founded	11 October 1991
Headquarters	Riga, Latvia
Area served	Worldwide
Key people	Kirovs Lipmans (Chairman) Juris Bundulis (CEO) Janis Romanovskis (Chief Finance and Administrative Officer)
Revenue	€ 82,7 million (2015)
Net income	€ 1.0 million (2015)
Owner	Kirovs Lipmans (33.29%)) Anna Lipmane (16.65%)
Number of employees	883 (2015)
Website	grindeks.lv

AS Grindeks (branded as Grindex), is a Latvian company listed on the with production of pharmaceutical drugs, medicine and medicine. The company was founded 17 October 1991 and is a since 25 August 1997.

One of the key drugs for Grindeks is meldonium, marketed under the trade name Mildronate. Meldonium is used for the treatment of angina and myocardial infarction by inhibiting the carnitine biosynthesis pathway via the inhibition of gamma-butyrobetaine dioxygenase.

In 2015, Grindeks had a turnover revenue of €82.7 million with a profit of €1.0 million. Grindeks had 883 employees and the main shareholders were Kirovs Lipmans (33.29%) and Anna Lipmane (16.65%)